Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 23 November 2017

Guerbet reinforces its expertise with the launch of Contrast&Care®, a contrast media injection management solution for radiology centers


Published: 08:00 CET 23-11-2017 /GlobeNewswire /Source: GUERBET / : GBT /ISIN: FR0000032526


Contrast&Care® has just obtained CE mark

Contrast&Care will be presented at the RSNA


Villepinte (France), November 23, 2017 (8:00 CET)
- Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, today announces the launch of Contrast&Care®, a new contrast media injection management solution for radiology centers.

The launch of the solution is part of the strategy of Guerbet to develop a portfolio of digital solutions to optimize the care and management of patients by healthcare professionals.

Contrast&Care® is an integrated IT solution that groups together all the information related to exams requiring the injection of contrast media (contrast media, injection protocol, patient data, etc.) and that interfaces with information systems used in radiology such as the Radiology Information System (RIS) or the Picture Archiving and Communication System (PACS).

The information generated by compatible injectors is transmitted automatically to Contrast&Care® at the end of each exam. This enables users to view the history of each patient, the exams with injection that have been performed and the doses of contrast media administered. Contrast&Care also offers the option of reviewing protocols, creating protocol libraries, and viewing statistics and trends relative to injection activity and the use of contrast media.

"Contrast&Care®was conceived by Guerbet to improve traceability and help healthcare professionals make decisions on a daily basis. With these new digital solutions, Contrast&Care® today, and Dose&Care® launched at the beginning of 2017, Guerbet has completed its integrated offers so radiology centers may make the most of the technological advances available today.", comments Levi Cheng, Director of the Imaging Solutions & Services Business Unit.

The commercial launch of Contrast&Care® will start at the beginning of 2018.

The Guerbet teams will present Contrast&Care® at all the upcoming international radiological congresses where specialists will perform interactive demonstrations (at the RSNA booth #1341 Hall A, the ECR, etc...).


About Contrast&Care®

Contrast&Care® is a class I /CE medical device designed to be used by healthcare professionals only. It is a contrast product injection management solution that enables imaging centers to collect, archive, examine and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate (eGFR) and other risk factors before an exam.


For more information, please refer to the information leaflet and instructions for use. Contrast&Care® is manufactured by Medex, a subsidiary of the Guerbet Group (Saint-Priest France).


About Dose&Care

Dose&Care® is a solution for managing and analyzing the dose of X Rays patients receive during medical imaging exams. It is intended for use by medical and diagnostic imaging professionals and by the personnel in charge of safety and X Ray administration in imaging centers.

For more information, please refer to the information leaflet and instructions for use.

Dose&Care® is a class I /CE medical device manufactured by MPTronic (Paris, France) and distributed by Guerbet, (Roissy CdG cedex, France).


About Guerbet

Guerbet is a pioneer in the contrast agent field with over 90 years' experience and is one of the leaders in medical imaging worldwide. The Group offers a full range of pharmaceutical products, medical devices and services for X-ray (RX) and Magnetic Resonance Imaging (MRI) scanners and Interventional Radiology Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue dedicated to R&D and more than 200 employees working in three centers in France and the United States, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B - Mid Caps) and generated €776 million in revenue in 2016. For more information about Guerbet, visit www.guerbet.com




Media Relations Contacts


Guerbet Global

Alize RP

Caroline Carmagnol et Wendy Rigal

+33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94





















Press Release

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: GUERBET, 15, rue des vanesses, Villepinte 95943, France
If you would like to unsubscribe and stop receiving these e-mails click here.